Literature DB >> 17641826

Long-term follow-up study of patients with phenylketonuria detected by the newborn screening programme in Japan.

K Aoki1, M Ohwada, T Kitagawa.   

Abstract

The objective of this report is to determine the need for and value of the long-term follow-up study of phenylketonuria (PKU) patients detected by newborn screening (NBS) in Japan. NBS was started in 1977 and the nationwide follow-up study of the identified patients was introduced into the NBS system. Outcome data from the continuous follow-up study showed in 1993 that IQ of PKU patients was inversely correlated with blood phenylalanine levels. Accordingly, in 1995, new treatment guidelines were issued that involved more stringent restriction of phenylalanine levels. Follow-up data confirmed that mean blood phenylalanine levels decreased after the introduction of the new guidelines, which included the recommendation to start dietary treatment within 20 days postpartum. Follow-up data also confirmed that dietary treatment did in fact commence earlier after the guidelines were issued. The need for lifelong dietary treatment is a difficult issue and the number of patients who stop dietary treatment was found to increase gradually with age. At present 60% of PKU patients born between 1977 and 1981 have stopped their dietary restriction of phenylalanine. The data gained from NBS and the long-term follow-up study were found to be valuable for the improvement of blood phenylalanine levels for patients with PKU, indicating the need for parties responsible for NBS and the follow-up study of the identified patients to work cooperatively. Further, the evaluations of the effectiveness of the two initiatives as well as the treatment guidelines issued should be based on outcome data, which depend on the continuation of the follow-up study of patients with PKU.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17641826     DOI: 10.1007/s10545-007-0602-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  6 in total

Review 1.  Current situation and prospects of newborn screening and treatment for Phenylketonuria in China - compared with the current situation in the United States, UK and Japan.

Authors:  Lin Mei; Peipei Song; Norihiro Kokudo; Lingzhong Xu; Wei Tang
Journal:  Intractable Rare Dis Res       Date:  2013-11

2.  Long-Term Neurological Outcomes of Adult Patients with Phenylketonuria before and after Newborn Screening in Japan.

Authors:  Kenji Yamada; Seiji Yamaguchi; Kazunori Yokoyama; Kikumaro Aoki; Takeshi Taketani
Journal:  Int J Neonatal Screen       Date:  2021-04-14

3.  Phenylketonuria in Portugal: Genotype-phenotype correlations using molecular, biochemical, and haplotypic analyses.

Authors:  Filipa Ferreira; Luísa Azevedo; Raquel Neiva; Carmen Sousa; Helena Fonseca; Ana Marcão; Hugo Rocha; Célia Carmona; Sónia Ramos; Anabela Bandeira; Esmeralda Martins; Teresa Campos; Esmeralda Rodrigues; Paula Garcia; Luísa Diogo; Ana Cristina Ferreira; Silvia Sequeira; Francisco Silva; Luísa Rodrigues; Ana Gaspar; Patrícia Janeiro; António Amorim; Laura Vilarinho
Journal:  Mol Genet Genomic Med       Date:  2021-01-19       Impact factor: 2.183

4.  A long-term study of bone mineral density in patients with phenylketonuria under diet therapy.

Authors:  Hala M Koura; Nagwa Abdallah Ismail; Ashraf F Kamel; Azza M Ahmed; Amal Saad-Hussein; Laila K Effat
Journal:  Arch Med Sci       Date:  2011-07-11       Impact factor: 3.318

5.  Diagnostic and therapeutic recommendations for the treatment of hyperphenylalaninemia in patients 0-4 years of age.

Authors:  Ania C Muntau; Marcel du Moulin; Francois Feillet
Journal:  Orphanet J Rare Dis       Date:  2018-09-29       Impact factor: 4.123

6.  Longitudinal quality of life analysis in a phenylketonuria cohort provided sapropterin dihydrochloride.

Authors:  Teresa D Douglas; Usha Ramakrishnan; Julie A Kable; Rani H Singh
Journal:  Health Qual Life Outcomes       Date:  2013-12-30       Impact factor: 3.186

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.